Renato José Silva-Oliveira1, Viviane Aline Oliveira Silva1, Olga Martinho1,2,3, Adriana Cruvinel-Carloni1, Matias Eliseo Melendez1, Marcela Nunes Rosa1, Flávia Escremim de Paula1, Luciano de Souza Viana1,4, André Lopes Carvalho1, Rui Manuel Reis5,6,7. 1. Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, CEP 14784 400, Barretos, São Paulo, Brazil. 2. Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal. 3. ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. 4. Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil. 5. Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, CEP 14784 400, Barretos, São Paulo, Brazil. ruireis.hcb@gmail.com. 6. Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal. ruireis.hcb@gmail.com. 7. ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. ruireis.hcb@gmail.com.
Abstract
BACKGROUND: The epidermal growth factor receptor (EGFR) is a member of the HER family of growth factors that activates several intracellular signaling pathways promoting proliferation and survival. EGFR over-expression is frequently associated with gene mutation or amplification, thereby constituting a major target for molecular therapies. Recently, a new generation of EGFR inhibitors has been developed with pan-HER properties and irreversible actions. Allitinib® (AST1306) is an orally active, highly selective irreversible inhibitor of the HER family of receptor tyrosine kinases with promising efficacies. In the present study we aimed to investigate the cytotoxicity of allitinib in a large panel of human cancer-derived cell lines and to correlate its efficacy to the mutational status of the EGFR, KRAS, BRAF, PI3KCA and PTEN genes. In addition, we aimed to evaluate the functional role of KRAS mutations in the response to this new inhibitor. RESULTS: In total 76 different cancer-derived cell lines, representing 11 distinct histological types, were analyzed and classified into three groups: highly sensitive (HS), moderately sensitive (MS) and resistant (R). We found that 28 (36.8 %) cancer-derived cell lines exhibited a HS phenotype, 19 (25.0 %) a MS phenotype and 29 (38.1 %) a R phenotype. Allitinib showed a stronger cytotoxicity in head and neck, esophageal, melanoma and lung cancer-derived cell lines. We found that KRAS mutations were significantly associated with the R phenotype. To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). We found that both mutations reverted the allitinib-sensitive phenotype in these cells. CONCLUSIONS: The current study represents the largest in vitro assessment of allitinib cytotoxicity performed to date. Through this study, we identified cancer types that could potentially benefit from this drug. Additionally, our findings suggest that prevalent KRAS mutations constitute potential predictive biomarkers for allitinib response.
BACKGROUND: The epidermal growth factor receptor (EGFR) is a member of the HER family of growth factors that activates several intracellular signaling pathways promoting proliferation and survival. EGFR over-expression is frequently associated with gene mutation or amplification, thereby constituting a major target for molecular therapies. Recently, a new generation of EGFR inhibitors has been developed with pan-HER properties and irreversible actions. Allitinib® (AST1306) is an orally active, highly selective irreversible inhibitor of the HER family of receptor tyrosine kinases with promising efficacies. In the present study we aimed to investigate the cytotoxicity of allitinib in a large panel of humancancer-derived cell lines and to correlate its efficacy to the mutational status of the EGFR, KRAS, BRAF, PI3KCA and PTEN genes. In addition, we aimed to evaluate the functional role of KRAS mutations in the response to this new inhibitor. RESULTS: In total 76 different cancer-derived cell lines, representing 11 distinct histological types, were analyzed and classified into three groups: highly sensitive (HS), moderately sensitive (MS) and resistant (R). We found that 28 (36.8 %) cancer-derived cell lines exhibited a HS phenotype, 19 (25.0 %) a MS phenotype and 29 (38.1 %) a R phenotype. Allitinib showed a stronger cytotoxicity in head and neck, esophageal, melanoma and lung cancer-derived cell lines. We found that KRAS mutations were significantly associated with the R phenotype. To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). We found that both mutations reverted the allitinib-sensitive phenotype in these cells. CONCLUSIONS: The current study represents the largest in vitro assessment of allitinibcytotoxicity performed to date. Through this study, we identified cancer types that could potentially benefit from this drug. Additionally, our findings suggest that prevalent KRAS mutations constitute potential predictive biomarkers for allitinib response.
Entities:
Keywords:
Allitinib; EGFR inhibitor; In vitro screening; KRAS mutation
Authors: Nadia Godin-Heymann; Ianthe Bryant; Miguel N Rivera; Lindsey Ulkus; Daphne W Bell; David J Riese; Jeffrey Settleman; Daniel A Haber Journal: Cancer Res Date: 2007-08-01 Impact factor: 12.701
Authors: Stine Louise Jeppe Knudsen; Anni Sieu Wai Mac; Lasse Henriksen; Bo van Deurs; Lene Melsæther Grøvdal Journal: Growth Factors Date: 2014-10 Impact factor: 2.511
Authors: Olga Martinho; Renato Silva-Oliveira; Vera Miranda-Gonçalves; Carlos Clara; José Reynaldo Almeida; André Lopes Carvalho; João Taborda Barata; Rui Manuel Reis Journal: Transl Oncol Date: 2013-04-01 Impact factor: 4.243
Authors: Marilia F Calmon; Rodrigo V Rodrigues; Carla M Kaneto; Ricardo P Moura; Sabrina D Silva; Louise Danielle C Mota; Daniel G Pinheiro; Cesar Torres; Alex F de Carvalho; Patrícia M Cury; Fabio D Nunes; Ines Nobuko Nishimoto; Fernando A Soares; Adriana M A da Silva; Luis P Kowalski; Helena Brentani; Cleslei F Zanelli; Wilson A Silva; Paula Rahal; Eloiza H Tajara; Dirce M Carraro; Anamaria A Camargo; Sandro R Valentini Journal: Neoplasia Date: 2009-12 Impact factor: 5.715
Authors: Barbara S Paugh; Xiaoyan Zhu; Chunxu Qu; Raelene Endersby; Alexander K Diaz; Junyuan Zhang; Dorine A Bax; Diana Carvalho; Rui M Reis; Arzu Onar-Thomas; Alberto Broniscer; Cynthia Wetmore; Jinghui Zhang; Chris Jones; David W Ellison; Suzanne J Baker Journal: Cancer Res Date: 2013-08-22 Impact factor: 12.701
Authors: J S Reis-Filho; C Pinheiro; M B K Lambros; F Milanezi; S Carvalho; K Savage; P T Simpson; C Jones; S Swift; A Mackay; R M Reis; J L Hornick; E M Pereira; F Baltazar; C D M Fletcher; A Ashworth; S R Lakhani; F C Schmitt Journal: J Pathol Date: 2006-08 Impact factor: 7.996
Authors: Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira Journal: Cell Oncol (Dordr) Date: 2019-11-07 Impact factor: 6.730
Authors: Taciane Macedo; Renato J Silva-Oliveira; Viviane A O Silva; Daniel O Vidal; Adriane F Evangelista; Marcia M C Marques Journal: Oncol Lett Date: 2017-05-26 Impact factor: 2.967
Authors: Viviane A O Silva; Ana Laura V Alves; Marcela N Rosa; Larissa R V Silva; Matias E Melendez; Fernanda P Cury; Izabela N F Gomes; Aline Tansini; Giovanna B Longato; Olga Martinho; Bruno G Oliveira; Fernanda E Pinto; Wanderson Romão; Rosy I M A Ribeiro; Rui M Reis Journal: Invest New Drugs Date: 2018-08-29 Impact factor: 3.850
Authors: Viviane A O Silva; Marcela N Rosa; Olga Martinho; Amilcar Tanuri; João Paulo Lima; Luiz F Pianowski; Rui M Reis Journal: Invest New Drugs Date: 2019-02-01 Impact factor: 3.850
Authors: Viviane A O Silva; Marcela N Rosa; Vera Miranda-Gonçalves; Angela M Costa; Aline Tansini; Adriane F Evangelista; Olga Martinho; Adriana C Carloni; Chris Jones; João Paulo Lima; Luiz F Pianowski; Rui Manuel Reis Journal: Invest New Drugs Date: 2018-06-22 Impact factor: 3.850
Authors: Renato José Silva-Oliveira; Gabriela Francine Lopes; Luiz Fernando Camargos; Ana Maciel Ribeiro; Fábio Vieira Dos Santos; Richele Priscila Severino; Vanessa Gisele Pasqualotto Severino; Ana Paula Terezan; Ralph Gruppi Thomé; Hélio Batista Dos Santos; Rui Manuel Reis; Rosy Iara Maciel de Azambuja Ribeiro Journal: Int J Mol Sci Date: 2016-11-08 Impact factor: 5.923
Authors: K M Santos; I N F Gomes; R J Silva-Oliveira; F E Pinto; B G Oliveira; R C R Chagas; W Romão; R M V Reis; R I M A Ribeiro Journal: Biomed Res Int Date: 2018-03-25 Impact factor: 3.411
Authors: Renato José Silva-Oliveira; Matias Melendez; Olga Martinho; Maicon F Zanon; Luciano de Souza Viana; André Lopes Carvalho; Rui Manuel Reis Journal: Oncotarget Date: 2017-06-07